Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation.


Journal Article

Initiation of antiretroviral therapy during acute HIV-1 infection may prevent persistent immune activation. We analyzed longitudinal CD38+HLA-DR+ CD8+ T-cell percentages in 31 acutely infected individuals who started early (median 43 days since infection) and successful antiretroviral therapy, and maintained viral suppression through 96 weeks. Pretherapy a median of 72.6% CD8+ T cells were CD38+HLA-DR+, and although this decreased to 15.6% by 96 weeks, it remained substantially higher than seronegative controls (median 8.9%, P = 0.008). Shorter time to suppression predicted lower activation at 96 weeks. These results support the hypothesis that very early events in HIV-1 pathogenesis may result in prolonged immune dysfunction.

Full Text

Cited Authors

  • Vinikoor, MJ; Cope, A; Gay, CL; Ferrari, G; McGee, KS; Kuruc, JD; Lennox, JL; Margolis, DM; Hicks, CB; Eron, JJ

Published Date

  • April 15, 2013

Published In

Volume / Issue

  • 62 / 5

Start / End Page

  • 505 - 508

PubMed ID

  • 23314410

Pubmed Central ID

  • 23314410

Electronic International Standard Serial Number (EISSN)

  • 1944-7884

Digital Object Identifier (DOI)

  • 10.1097/QAI.0b013e318285cd33


  • eng

Conference Location

  • United States